C ardiovascular complications are the leading cause of mortality and morbidity in patients with diabetes mellitus, and numerous lines of evidence suggest that systemic metabolic abnormalities, which accompany diabetes mellitus, like hyperglycemia, hyperinsulinemia, and dyslipidemia, are associated with accelerated atherosclerosis. 1 Elevated levels of diacylglycerol, formed as a result of a high concentration of glucose and nonesterified fatty acids, lead to the activation of protein kinase C (PKC). 2 This event is thought to be one of the links between abnormal metabolism and altered vascular cell signaling in the conditions of diabetes mellitus and atherosclerosis. In this respect, it was proposed some time ago that PKC isoforms play an important role in vascular inflammation via the induction of proinflammatory cytokine expression, activation of nuclear factor κB and NADPH oxidase, increase of several signaling proteins, such as extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (MAPK), and dysfunction of endothelial NO synthase. 3 In line with this evidence, PKCβ deficiency resulted in attenuated atherosclerosis in apolipoprotein E (Apoe −/− ) mice via significantly reduced vascular early growth response-1 (Egr-1) and matrix metalloproteinase-2 expression. 4
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In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Kong et al 5 demonstrate that activated plasma membrane-bound PKCβ is elevated in the aortas of low dose streptozotocin-induced hyperglycemic Apoe −/− mice, and that PKCβ antagonism is sufficient to reduce accelerated atherosclerotic plaque burden in hyperglycemic Apoe −/− mice to levels comparable with the euglycemic Apoe −/− mice. Researchers have recognized the potential role of PKC isoforms and, particularly, PKCβ in diabetes mellitus and atherosclerosis for many years. 3 This study provides an additional evidence for the involvement of PKCβ in inflammation targeting both vascular and leukocyte sites. It is important to mention that the significant reduction of atherosclerosis in Pkcb −/− Apoe −/− mice was detected under conditions of similar levels of glucose, cholesterol, and triglycerides compared with Apoe −/− mice highlighting a direct effect of PKCβ on atherogenesis.
The authors show that PKCβ is responsible for the upregulation of Egr-1, Erk1/2, and Jun NH2-terminal kinase (JNK) levels and subsequent induction of a broad spectrum of proinflammatory cytokines and adhesion molecules in diabetic Apoe −/− mice. Previous studies involving Egr-1 6 and PKCβ 7 deficient bone marrow in transplanted Ldlr -/mice have highlighted a pro-atherogenic role for Egr-1 via the regulation of a wide set of proinflammatory genes and implicated Egr-1-dependent Ras-Raf-MEK-ERK signaling pathway in this process. Therefore, it is not quite surprising that hyperglycemic Apoe −/− mice, which show elevated levels of PKCβ, demonstrate PKC-induced Egr-1-dependent induction of proinflammatory mediators during atherogenesis. To further examine the mechanisms behind hyperglycemia-accelerated atherosclerosis in this system, several broad markers of inflammation, including expression of several proinflammatory cytokines, chemokines, and adhesion molecules, and lesional macrophage content were examined. As expected based on the lesion data, hyperglycemic Apoe −/− mice displayed broadly elevated levels of multiple proinflammatory mRNA transcripts, including Ccl2, Itgax, Itgb2, and others, whereas PKCβ-deficient hyperglycemic Apoe −/− mice and euglycemic Apoe −/− mice expressed comparable levels of these genes. Additionally, deficiency of PKCβ resulted in diminished lesional macrophages and CD11c-expressing cells in diabetic Apoe −/− mice. To extend these results, Kong et al 5 also cultured U937 macrophages in vitro in high glucose conditions both with and without PKCβ, Erk1/2, JNK, and p38 antagonists. U937 macrophages upregulated Egr-1, CD11c, Ccl2, and Il1b transcripts under high glucose in a PKCβ, Erk1/2, and Jnk-dependent manner. Together, these data have furnished a novel link between the activation of PKCβ and the regulation of leukocyte content within aortas of hyperglycemic Apoe −/− mice (Figure) . It remains to be determined whether PKCβ has a direct effect on the recruitment of macrophages and potentially CD11c + dendritic cells into aortas or whether PKCβ impacts the proinflammatory status of aortic vascular cells and thus support myeloid cell migration into vessel wall. In this respect, it is also important to note that all of the detected effects in diabetic Apoe −/− mice were observed in the conditions of global PKCβ deficiency. Future studies will be required to determine the precise contributions of vascular and hematopoietic PKCβ signaling toward hyperglycemia-accelerated atherogenesis.
Type 2 diabetes mellitus is known to be associated with multiple systemic metabolic abnormalities, including hyperglycemia but also hyperinsulinemia, and dyslipidemia. 8 In this regard, defective insulin signaling has been shown to have a proatherogenic effects in several models of insulin resistanceaccelerated atherosclerosis. 9 Although the streptozotocininduced Apoe −/− mouse model is a good model to study the impact of hyperglycemia on atherogenesis, it does not completely mimic the conditions of type 2 diabetes mellitus.
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Although PKCβ and hyperglycemia is certainly involved in diabetes mellitus-accelerated atherosclerosis, other metabolic perturbations may similarly affect the development and severity of atherosclerosis. In the study by Kong et al, 5 the streptozotocin-treated Apoe −/− mouse model of diabetes mellitus provides an extreme condition of persistently elevated glucose exposure during atherogenesis. Additionally, although the authors maintain high levels of plasma glucose in streptozotocin-treated Apoe −/− mice during the development of atherosclerosis without any treatments, blood glucose levels are regulated in patients with diabetes mellitus. Thus, the results from this study may not accurately recapitulate the diabetic human condition, but nonetheless these data provide a proof of concept for the implication of PKCβ in diabetes mellitusaccelerated atherosclerosis. Several clinical trials that have investigated the effects of intensive glucose lowering for the reduction of cardiovascular risk have presented conflicting evidence with different outcomes, indicating a long-term cardiovascular benefit in some, but not other studies. 8 The results from this study reveal an additional role of PKCβ in the support of atherosclerosis in hyperglycemic conditions and imply that PKCβ inhibitors may be therapeutically useful. Recently, ruboxistaurin, a PKCβ inhibitor that is relatively well-tolerated by patients with diabetes mellitus, 10 demonstrated positive improvement on cardiac function in a porcine model of heart failure. 11 Future studies in animal models and large-scale, long-term clinical trials will help to identify the benefits of PKCβ blockade for the prevention of vascular complications associated with diabetes mellitus. PKCβ, an old suspect in cardiovascular morbidity and mortality, remains interesting for the scientific and clinical community.
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Figure.
Potential effects of hyperglycemiainduced PKCβ signaling in diabetes mellitus-accelerated atherosclerosis. As a result of hyperglycemia, vascular PKCβ signaling through Erk1/2, Jnk, and Egr-1 has various effects on cellular components of the atherosclerotic plaque. Factors and processes that may be affected by PKCβ signaling but have not been demonstrated are denoted by question marks (?). ↑ indicates increase.
